| Literature DB >> 29625255 |
Patrick Ejlerskov1, Avraham Ashkenazi2, David C Rubinsztein3.
Abstract
Most of the neurodegenerative diseases that afflict humans manifest with the intraneuronal accumulation of toxic proteins that are aggregate-prone. Extensive data in cell and neuronal models support the concept that such proteins, like mutant huntingtin or alpha-synuclein, are substrates for macroautophagy (hereafter autophagy). Furthermore, autophagy-inducing compounds lower the levels of such proteins and ameliorate their toxicity in diverse animal models of neurodegenerative diseases. However, most of these compounds also have autophagy-independent effects and it is important to understand if similar benefits are seen with genetic strategies that upregulate autophagy, as this strengthens the validity of this strategy in such diseases. Here we review studies in vertebrate models using genetic manipulations of core autophagy genes and describe how these improve pathology and neurodegeneration, supporting the validity of autophagy upregulation as a target for certain neurodegenerative diseases.Entities:
Keywords: ATG5; ATG7; Autophagy; Beclin 1; Genetic therapy; Neurodegenerative disease
Mesh:
Year: 2018 PMID: 29625255 DOI: 10.1016/j.nbd.2018.04.001
Source DB: PubMed Journal: Neurobiol Dis ISSN: 0969-9961 Impact factor: 5.996